Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDUA | P35475 | 1/20 | 0.36 |
| ▸ | CAD | P27708 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999553 | 1.00 | P2RX7 (0.40) | P2RX7HTTCYP2D6LMNABLM | |
| SCHEMBL5081569 | 1.00 | P2RX7 (0.40) | P2RX7HTTCYP2D6LMNABLM | |
| SCHEMBL5365854 | 1.00 | P2RX7 (0.40) | P2RX7HTTCYP2D6LMNABLM | |
| Hydrochloric Acid SCHEMBL28572830 | 0.98 | P2RX7 (0.39) | P2RX7HTTCYP2D6LMNABLM | |
| SCHEMBL8232195 | 0.83 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL25251069 | 0.81 | P2RX7 (0.39) | P2RX7ACE | |
| SCHEMBL8067332 | 0.81 | P2RX7 (0.36) | P2RX7 | |
| Lithium Ion SCHEMBL30619228 | 0.79 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL6992243 | 0.79 | HTT (0.37) | HTTCYP2D6LMNABLMALOX15 | |
| SCHEMBL8231725 | 0.78 | BRD4 (0.49) | P2RX7CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007029267-A1 | PROCESS FOR INDUSTRIALLY VIABLE PREPARATION OF IMIDAPRIL HYDROCHLORIDE | POTLURI RAMESH BABU (IN) | 2007-03-15 | — | — | WO | claimed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023205618-A2 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3985001-A1 | PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| CN-1139599-C | Process for the preparation of pharmacologically acceptable salts of N- (1(S) -ethoxycarbonyl-3-phenylpropyl) -L-alanyl-amino acids | ��Ԩ��ѧ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| US-6518436-B2 | Condensing an amino acid and N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine-N-carboxy-anhydride; suppressing the by-product diketopiperazine derivative; making enalapril maleate | KANEKA CORPORATION (JP) | 2003-02-11 | — | — | US | disclosed |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2002-07-04 | — | — | US | disclosed |
| US-6335453-B1 | BY-PROUDCT INHIBITION | KANEKA CORPORATION (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-0967221-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-12-29 | — | — | EP | disclosed |
| CN-1234804-A | Process for preparing pharmacologically acceptable salts of N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids | KANEKA CHEMICAL IND CO LTD (JP) | 1999-11-10 | — | — | CN | disclosed |
| EP-0373881-A2 | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-20 | — | — | EP | disclosed |
| EP-0095163-A2 | 2-Oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition | Tanabe Seiyaku Co., Ltd. (JP) | 1983-11-30 | — | — | EP | disclosed |
| EP-0052696-A1 | Novel 2-oxoimidazolidine derivative, a process for preparing same and a pharmaceutical composition containing the 2-oxoimidazolidine derivative | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | P2RX7 4769/4885HTT 3602/4885CYP2D6 4759/4885 |
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | P2RX7 3949/4885HTT 1738/4885CYP2D6 1307/4885 |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | P2RX7 4549/4885HTT 303/4885CYP2D6 1949/4885 |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | P2RX7 3949/4885HTT 1738/4885CYP2D6 1307/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | P2RX7 4549/4885HTT 303/4885CYP2D6 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.